journal
https://read.qxmd.com/read/37555194/hereditary-renal-cell-carcinoma-is-age-an-independent-criterion-for-genetic-testing-a-large-cohort-from-a-latin-america-referral-center
#21
JOURNAL ARTICLE
Tomás Carminatti, Patricio Aitor García Marchiñena, Ignacio Pablo Tobia González, Valeria de Miguel, Marcelo Martín Serra, Pablo Germán Kalfayan, Alberto Manuel Jurado
Although age younger than 46 years has been an independent criterion for genetic testing in hereditary renal cell carcinoma (hRCC), there is a lack of evidence in the literature. This study aims to analyze whether a 46-year-old cut-off should be considered an independent genetic testing criterion and to elucidate risk factors predicting a positive genetic test. Observational study from January 2010 to December 2021. All patients under 46 years with a non-metastatic kidney mass and surgical indication were included...
2023: Journal of Kidney Cancer and VHL
https://read.qxmd.com/read/37457633/comparison-of-posterior-and-antero-lateral-renal-tumors-in-retroperitoneal-laparoscopic-partial-nephrectomy-a-propensity-score-matching-analysis
#22
JOURNAL ARTICLE
Hakan Anıl, Ali Yıldız, Ahmet Güzel, Serkan Akdemir, Kaan Karamık, Murat Arslan
This study aimed to compare the antero-lateral and posterior localized renal masses in laparoscopic partial nephrectomy with the retroperitoneal approach in terms of operative, functional, and oncological outcomes. Patients who underwent retroperitoneal laparoscopic partial nephrectomy by a single surgeon between January 2013 and January 2021 were included in the study. A one-to-one propensity score matching (PSM) analysis was conducted to obtain two balanced groups. The patients were divided into two groups as posterior and antero-lateral according to the localization of the mass...
2023: Journal of Kidney Cancer and VHL
https://read.qxmd.com/read/37441361/chromophobe-renal-cell-carcinoma-with-sarcomatoid-differentiation
#23
Benjamin J Lichtbroun, Brian Shinder, Tina Gowda Sara, Arnav Srivastava, Biren Saraiya, Tina M Mayer, Ryan Cristelli, Evita Sadimin, Robert E Weiss, Eric A Singer
Chromophobe renal cell carcinoma (chRCC) is one of the less common types of kidney cancer and generally portends a more favorable prognosis. RCC with sarcomatoid differentiation has a more aggressive clinical course with poor outcomes. Four cases of chRCC with varying degrees of sarcomatoid differentiation were retrospectively reviewed at our institution, and clinicopathologic data as well as clinical courses were reported. Patients with higher degrees of sarcomatoid differentiation and larger tumors at presentation generally had and worse overall survival...
2023: Journal of Kidney Cancer and VHL
https://read.qxmd.com/read/37404672/role-of-angular-interface-sign-in-characterizing-small-exophytic-renal-masses-in-computed-tomography-prospective-study
#24
JOURNAL ARTICLE
Mohamed Sharafeldeen, Mohamed Shaaban, Ahmed Hafez Afif, Mohamed Elsaqa, Nagy Naguib, Sara Elnaggar, Ahmad Beltagy
The widespread use of computed tomography (CT) has increased the incidence of small renal cell masses. We aimed to evaluate the usefulness of the angular interface sign (ice cream cone sign) to differentiate a broad spectrum of small renal masses using CT. The prospective study included CT images of patients with exophytic renal masses ≤ 4 cm in maximal dimension. The presence or absence of an angular interface of the renal parenchyma with the deep part of the renal mass was assessed. Correlation with the final pathological diagnosis was performed...
2023: Journal of Kidney Cancer and VHL
https://read.qxmd.com/read/37398509/leiomyoma-of-kidney
#25
Vishnu Karayil R, Mini Bhaskarashenoy, Geetha Sukumaran
Renal leiomyomas are rare benign mesenchymal tumors of kidney that affect adults of second to sixth decade. They can present as small asymptomatic multifocal lesions that are identified only in autopsy, or as large solitary lesions that cause pain and abdominal distention. Histomorphologically it appears exactly like its counterpart in other soft tissues. Differentiating renal leiomyoma from the lipid-poor angiomyolipoma is difficult by morphology, hence immunohistochemical studies are recommended. The case described is that of a female patient aged 74 years with a small solitary lesion in right kidney, who presented with history of pain and abdominal distention...
2023: Journal of Kidney Cancer and VHL
https://read.qxmd.com/read/37303946/management-outcomes-of-large-renal-angiomyolipoma-presenting-with-wunderlich-syndrome-experience-from-a-tertiary-center
#26
JOURNAL ARTICLE
Atanu Kumar Pal, Sidhartha Kalra, Sreerag Kodakkattil Sreenivasan, Lalgudi Narayanan Dorairajan, Ramanitharan Manikandan, Shailendra Kumar Sah
Renal angiomyolipoma is an uncommon, benign-mixed mesenchymal tumor consisting of thick-walled blood vessels, smooth muscles, and mature adipose tissues. Twenty percent of these tumors are associated with tuberous sclerosis. Wunderlich syndrome (WS), an acute nontraumatic spontaneous perirenal hemorrhage, can be a presentation of large angiomyolipoma. This study evaluated the presentation, management, and complications of renal angiomyolipoma with WS in eight patients who presented to the emergency department between January 2019 and December 2021...
2023: Journal of Kidney Cancer and VHL
https://read.qxmd.com/read/37251595/von-hippel-lindau-is-associated-to-pancreatic-neuroendocrine-tumors-a-comprehensive-review
#27
JOURNAL ARTICLE
Danilo Coco, Silvana Leanza
Multiorgan tumors are a hallmark of the autosomal dominant genetic disorder known as Von Hippel-Lindau syndrome (VHL), which is typically the result of inherited aberrations of the VHL tumor suppressor gene. The most frequent cancer is retinoblastoma, which can also occur in the brain and spinal cord, renal clear cell carcinoma (RCCC), paraganglioma, and neuroendocrine tumors. There may also be lymphangiomas, epididymal cysts, and pancreatic cysts or pancreatic neuroendocrine tumors (pNETs). The most frequent causes of death are metastasis from RCCC and neurological complications from retinoblastoma or central nervous system (CNS)...
2023: Journal of Kidney Cancer and VHL
https://read.qxmd.com/read/37197692/primary-well-differentiated-neuroendocrine-tumor-of-the-kidney
#28
Vishnu Prasad, Charakkulam Vijay Sreelakshmi, K Ravi Chandran, Shashank Agrawal, Ginil Kumar Pooleri, Amrita Sao
Primary neuroendocrine tumors (NET) of the kidney are rare. They present with varied symptoms, making their diagnosis difficult clinically as well as pathologically. We present to you the case of a renal NET, which presented in a young female patient. A 48-year-old female patient came with an incidentally detected right renal mass during the evaluation of a nonspecific gynecological problem. She underwent contrast-enhanced computed tomography (CT) of the abdomen, which showed a 57*45*34 mm mass with enlarged retrocaval and aortocaval nodes (25*12 mm)...
2023: Journal of Kidney Cancer and VHL
https://read.qxmd.com/read/37159585/renal-cell-carcinoma-arising-from-isthmus-of-horseshoe-k
#29
Sanjay M Khaladkar, Sai Sabari Vinay Kumar Parripati, Deepak Koganti, Satvik Dhirawani, Urvashi Agarwal
The most common congenital renal fusion anomaly is the horseshoe kidney (HSK) occurring in about 1 in 600-700 individuals in the Indian population. HSKs are associated with problems such as renal stones, obstruction of uretero-pelvic junction causing stasis, and infection due to ectopic location of the kidneys, malrotation of the kidneys, and vascular changes. In general, normally developed kidneys have more incidents of renal cell carcinoma (RCC) as compared to HSKs. The major issue arises during surgery of HSK due to their altered anatomy and aberrant blood supply...
2023: Journal of Kidney Cancer and VHL
https://read.qxmd.com/read/37123102/screening-for-latent-polycythemia-vera-in-renal-cell-carcinoma-associated-erythrocytosis
#30
JOURNAL ARTICLE
Stephen E Langabeer
No abstract text is available yet for this article.
2023: Journal of Kidney Cancer and VHL
https://read.qxmd.com/read/36969300/mayo-adhesive-probability-score-does-not-have-prognostic-ability-in-locally-advanced-renal-cell-carcinoma
#31
JOURNAL ARTICLE
Benjamin N Schmeusser, Tad A Manalo, Yuan Liu, Yash B Shah, Adil Ali, Manuel Armas-Phan, Dattatraya H Patil, Reza Nabavizadeh, Kenneth Ogan, Viraj A Master
Nephrectomy remains standard treatment for renal cell carcinoma (RCC). The Mayo Adhesive Probability (MAP) score is predictive of adherent perinephric fat and associated surgical complexity, and is determined by assessing perinephric fat and stranding. MAP has additionally predicted progression-free survival (PFS), though primarily reported in stage T1-T2 RCC. Here, we examine MAP's ability to predict overall survival (OS) and PFS in T3-T4 RCC. From our prospectively maintained RCC database, patients that underwent radical nephrectomy (2009-2016) with available abdominal imaging (<90 days preop) and T3/T4 RCC underwent MAP scoring...
2023: Journal of Kidney Cancer and VHL
https://read.qxmd.com/read/36816596/delayed-cardiac-metastasis-from-renal-cell-carcinoma-caused-by-vhl-mutation
#32
Christopher L Sudduth, Anthony Castagno, Peter Maggs
Cardiac metastasis caused by renal cell carcinoma (RCC) without vena caval involvement is rare. No mutation has been associated with this unique phenotype. A 77-year-old male presented to our clinic with a symptomatic right ventricular mass after nephrectomy for clear cell RCC (ccRCC). The mass was resected, and metastatic disease was confirmed. Targeted exon sequencing identified a VHL mutation (c.494T > G, p.V165G) in the resected specimen. While more than half of ccRCC cases are associated with VHL mutations, this case is the first to show the association between delayed, isolated cardiac metastasis and VHL V165G mutation...
2023: Journal of Kidney Cancer and VHL
https://read.qxmd.com/read/36793395/the-significance-of-serum-c-reactive-protein-and-neutrophil-lymphocyte-ratio-in-predicting-the-diagnostic-outcomes-of-renal-mass-biopsy-procedure
#33
JOURNAL ARTICLE
Aykut Colakerol, Sergen Sahin, Ramazan Omer Yazar, Mustafa Zafer Temiz, Emrah Yuruk, Engin Kandirali, Atilla Semercioz, Ahmet Yaser Muslumanoglu
This study aimed to investigate the predictive role of serum C-reactive protein (CRP) and neutrophil-to-lymphocyte ratio (NLR) on renal mass biopsy outcomes. A total of 71 patients with suspected kidney masses who underwent renal mass biopsy procedure between January 2017 and January 2021 were retrospectively evaluated. Pathological results after the procedure were obtained and pre-procedural serum CRP and NLR levels were extracted from the patients' data. The patients were grouped into benign and malignant pathology groups according to the histopathology results...
2023: Journal of Kidney Cancer and VHL
https://read.qxmd.com/read/36713028/ligustrazine-inhibits-the-migration-and-invasion-of-renal-cell-carcinoma
#34
Xufeng Zhang, Junfu Wang, Yanhua Cao, Kalin Li, Chao Sun, Wen Jiang, Qian Xin, Jue Wang, Tonggang Qi, Shuangde Liu, Yun Luan
Ligustrazine is a Chinese herb ( Chuanxiong) approved for use as a medical drug in China. Recent evidence suggests that ligustrazine has promising antitumor properties. Our preliminary results showed that ligustrazine could inhibit the growth of human renal cell carcinoma (RCC) cell lines. However, the complicated molecular mechanism has not been fully revealed. Therefore, the purpose of this study to investigate the mechanism of ligustrazine resistance in human RCC cells. Cell proliferation, migration, invasion, and colony-formation ability of RCC cells A498 were detected by MTT assay, clonal formation rates, and transwell chamber assay in vitro ...
2023: Journal of Kidney Cancer and VHL
https://read.qxmd.com/read/36578280/inflammatory-myofibroblastic-tumor-of-the-right-kidney-mimicking-a-locally-advanced-renal-carcinoma-a-case-report
#35
Ali Ariafar, Faisal Ahmed, AbdolAzim Khorshidi, Simin Torabi-Nezhad, Seyed Hossein Hosseini
An inflammatory myofibroblastic tumor (IMT) is a rare neoplasm with an unclear origin that can arise anywhere on the body. It contains spindle cells (myofibroblasts) with different inflammatory elements. Primary IMT of the kidney is a clinically rare disease and is difficult to differentiate from other renal malignancies. We reported a 49-year-old male who presented with right flank pain in the past year. A computed tomography scan showed a mixed density with slight heterogeneous enhancement mass in the upper pole of the right kidney, two small hypodense nodules invading the liver, and another mass in the lateral aspect of inferior vena cava...
2022: Journal of Kidney Cancer and VHL
https://read.qxmd.com/read/36381239/a-case-report-mucinous-tubular-and-spindle-cell-carcinoma-of-kidney-with-spindle-cell-predominance-mimicking-mesenchymal-tumour
#36
Natarajan Ramya, Murhekar Kanchan, Raja Anand, Sundersingh Shirley
Mucinous tubular and spindle cell carcinoma (MTSCC) of kidney is a rare variant of renal cell carcinoma which was first described in the 2004 World Health Organization classification of tumours of the kidney. Morphologically, MTSCC is composed of tubules merging with bland-appearing spindle cells in a myxoid/mucinous stroma. Diverse morphological patterns have been reported in MTSCC; however, a spindle cell predominant morphology mimicking a mesenchymal tumour is rare and only two cases have been reported so far...
2022: Journal of Kidney Cancer and VHL
https://read.qxmd.com/read/36381238/mucinous-tubular-and-spindle-cell-renal-cell-carcinoma-mtsc-rcc-with-an-unusual-presentation-in-a-child
#37
Kanika Sharma, Anjan Dhua, Sandeep Agarwala, Seema Kaushal
Mucinous tubular and spindle cell renal cell carcinoma (MTSC-RCC) is a rare but favorable variant of renal cell carcinoma, predominantly found in adults. Complete surgical excision is the treatment of choice. We are reporting an intriguing case of bilateral MTSC-RCC in a 13-year-old-boy with rapid disease progression, leading to metastatic disease and subsequent demise of the child.
2022: Journal of Kidney Cancer and VHL
https://read.qxmd.com/read/36313129/partial-nephrectomy-for-t1b-t2-renal-mass-an-added-shift-from-radical-nephrectomy
#38
JOURNAL ARTICLE
Mohamed Sharafeldeen, Wael Sameh, Vahid Mehrnoush, Amer Alaref, Radu Rozenberg, Asmaa Ismail, Hazem Elmansy, Walid Shahrour, Ahmed Zakaria, Osama Elmeslemany, Nishigandha Burute, Anatoly Shuster, Owen Prowse, Ahmed Kotb
The aim of our study was to show our short-term experience in managing large renal masses (cT1b/T2) through partial nephrectomy (PN) over the last 3 years. Retrospective data collection for all patients managed by PN for renal masses larger than 4 cm over the last 3 years. Epidemiological data were collected. Surgical data including surgical and ischemic times as well as intra and postoperative complications were collected. Pre- and postoperative estimated glomerular filtration rate (eGFR) data were collected and correlated as well as postoperative complications and recurrence...
2022: Journal of Kidney Cancer and VHL
https://read.qxmd.com/read/36310639/current-options-for-second-line-systemic-therapy-in-metastatic-renal-cell-carcinoma
#39
REVIEW
Iraklis C Mitsogiannis, Maria Mitsogianni, Maria Papathanassiou, Maria Anagnostou, Ioannis Tamposis, Lampros Mitrakas, Maria Samara, Vassilios Tzortzis, Panagiotis J Vlachostergios
Standard systemic therapy of advanced renal cell carcinoma (RCC) involves targeting angiogenesis, mainly through tyrosine kinase inhibitors (TKI) against the vascular endothelial growth factor receptor (VEGFR) pathway and targeting the immune checkpoints, namely, programmed death-1 (PD-1) or its ligand (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA4). With current strategies of combining these two approaches in the front-line setting, less is known about optimal selection of therapy upon development of resistance in the second and later lines of treatment for progressive disease...
2022: Journal of Kidney Cancer and VHL
https://read.qxmd.com/read/36310638/understanding-the-impact-of-belzutifan-on-treatment-strategies-for-patients-with-vhl
#40
JOURNAL ARTICLE
Aileen Arevalo, Neal Patel, Peter Muraki, Shinji Ohtake, Gennady Bratslavsky, Chandra Clark, Joshua Mann, Othon Iliopoulos, Eric Jonasch, Ramaprasad Srinivasan, Brian Shuch
Belzutifan was recently approved for the management of Von Hippel-Lindau disease (VHL). Given the morbidity of recurrent treatment, systemic therapy to reduce or eliminate the need for surgery has been long-awaited. Herein, we sought to gain insight about future utilization by surveying VHL kidney cancer experts in the United States. A survey developed by members of the VHL Alliance (VHLA) Clinical Advisory Council was distributed to kidney cancer providers at VHLA and National Comprehensive Cancer Network (NCCN) centers...
2022: Journal of Kidney Cancer and VHL
journal
journal
54244
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.